Other male erectile dysfunction
Methodology & AI Transparency ⓘ
Other male erectile dysfunction Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Designated in federal medical registries as N52.8, Other male erectile dysfunction falls under Men's Health & TRT management, where PDE5 vascular therapy [Other male erectile dysfunction N52.8] establishes baseline severity and rules out diagnostic mimics.
- 2 Real-world patient consensus: Diagnostic registry N52.8: Other male erectile dysfunction is managed within Men's Health & TRT.
- 3 Typical cash cost range: Workup highlights for Other male erectile dysfunction (N52.8): PDE5 vascular therapy [Other male erectile dysfunction N52.8].
- 4 Top reported side effects / signs: Key Men's Health & TRT biomarkers for Other male erectile dysfunction (N52.8): LH, FSH & in Other male erectile dysfunction (N52.8: SHBG) & Hematocrit & Total in Other male erectile dysfunction (N52.8: PSA) (Hct < 50%; age-appropriate PSA (N52.8)).
Ask our AI Specialists anything about Other male erectile dysfunction
What Is Other male erectile dysfunction?
Designated in federal medical registries as N52.8, Other male erectile dysfunction falls under Men's Health & TRT management, where PDE5 vascular therapy [Other male erectile dysfunction N52.8] establishes baseline severity and rules out diagnostic mimics.
Pathophysiology, Underlying Causes & Clinical Presentation
Biological expression of Other male erectile dysfunction (N52.8, Men's Health & TRT) reflects impaired cavernosal endothelial in Other male erectile dysfunction (N52.8: nitric oxide-cGMP smooth-muscle). longitudinal control is benchmarked via LH, FSH & in Other male erectile dysfunction (N52.8: SHBG).
Common Symptoms & Clinical Signs
- • Presentation of Other male erectile dysfunction (N52.8): reduced sexual desire, in Other male erectile dysfunction (N52.8: fewer spontaneous morning)
- • Secondary Other male erectile dysfunction clinical sign: loss of lean in Other male erectile dysfunction (N52.8: muscle recovery, rising)
- • Symptom flares in Other male erectile dysfunction correlating with LH, FSH & in Other male erectile dysfunction (N52.8: SHBG) deviation outside LH/FSH 2.5 – 8.0 mIU/mL (N52.8)
- • Functional men's health & trt impact requiring PDE5 vascular therapy [Other male erectile dysfunction N52.8] evaluation (N52.8)
Other male erectile dysfunction Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | N52.8 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Men's Health, Testosterone & Sexual Function | NLM Clinical Tables |
| Diagnostic / Lab Marker: LH, FSH & in Other male erectile dysfunction (N52.8: SHBG) | LH/FSH 2.5 – 8.0 mIU/mL (N52.8) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Hematocrit & Total in Other male erectile dysfunction (N52.8: PSA) | Hct < 50%; age-appropriate PSA (N52.8) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Ultrasensitive Estradiol & in Other male erectile dysfunction (N52.8: ApoB) | E2 20–38 pg/mL; ApoB < 80 mg/dL (N52.8) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Other male erectile dysfunction
Treatment selection for Other male erectile dysfunction depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Other male erectile dysfunction)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Valsartan vs. other angiotensin II receptor blockers in the treatment of high: What a 13,110-Participant Study Found Valsartan administered at 160 or 320 mg is more effective at lowering BP than losartan 100 mg and shows comparable efficacy to other ARBs in patients with essential high blood pressure. International journal of clinical practice • 2009-05-15 • Meta-Analysis | N = 13,110 | 99/100 | PMID 19392925 ↗ |
| New Insights on Efficacy comparison of monotherapies and combination therapies for androgenetic: What a 3,133-Participant Study Found In recent years, combination therapies are showing significant promise as potential therapies. Dermatologic therapy • 2022-03-15 • Meta-Analysis | N = 3,133 | 99/100 | PMID 34897933 ↗ |
| New Insights on Association between testosterone replacement therapy and heart and blood vessel: What a 11,502-Participant Study Found Our analysis indicates that for patients with hypogonadism, testosterone replacement therapy does not increase the CVD risk and all-cause mortality. Progress in cardiovascular diseases • 2024-01-15 • Meta-Analysis | N = 11,502 | 99/100 | PMID 38589271 ↗ |
| New Insights on Combination Therapy in Androgenetic hair loss: A Network Meta-Analysis of: What a 3,012-Participant Study Found Based on the current studies, we found that the combination of Minoxidil with spironolactone, PRPF, flutamide, and finasteride may offer better treatment outcomes for patients with androgenetic hair loss. Aesthetic plastic surgery • 2026-07-15 • Meta-Analysis | N = 3,012 | 99/100 | PMID 42168420 ↗ |
| New Insights on Safety profile of telmisartan as single-drug treatment or combined with: What a 8,023-Participant Study Found The consolidated data show that telmisartan +/- HCTZ are well tolerated in patients of all ages and have placebo-like tolerabilities. Blood pressure. Supplement • 2008-06-15 • Randomized Controlled Trial | N = 8,023 | 96/100 | PMID 18705533 ↗ |
Other male erectile dysfunction Patient Community & “People Like Me” Threads
Filter Other male erectile dysfunction community threads and patient logs by age, biological sex, dosage, and treatment duration.